Skip to main content
Back to homepage
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Coverage Analysts
SEC Filings
SEC Filings
Annual Reports & Proxies
Governance
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Email Alerts
Contact
Menu
Press Releases
Overview
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Coverage Analysts
SEC Filings
SEC Filings
Annual Reports & Proxies
Governance
Executive Management
Board of Directors
Committee Composition
Resources
Investor FAQs
Email Alerts
Contact
Normal
Press release year list
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
December 05, 2015
ADC Therapeutics Announces Positive Pre-clinical Results for Two of its Novel ADCs at the American Society of Hematology Conference
Download
PDF format download (opens in new window)
December 04, 2015
ADC Therapeutics Receives FDA Clearance to Begin Clinical Studies for its Second Novel Antibody Conjugate ADCT-402 against Lymphomas and Leukemia
Download
PDF format download (opens in new window)
September 28, 2015
ADC Therapeutics Announces Expanded Board with Appointment of Highly Experienced Non-Executive Directors
Download
PDF format download (opens in new window)
September 05, 2015
ADC Therapeutics Secures $80m Financing to Progress its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology
Download
PDF format download (opens in new window)
June 22, 2015
ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer
Download
PDF format download (opens in new window)
April 19, 2015
ADC Therapeutics Presented Positive Pre-clinical Activity of its Novel Anti-CD22 Antibody-Drug Conjugate at the American Association for Cancer Research (AACR) Annual Meeting
Download
PDF format download (opens in new window)
March 16, 2015
ADC Therapeutics Submits its First IND For a Novel Antibody Drug Conjugate Against Lymphomas
Download
PDF format download (opens in new window)